Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.65 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31042226 | 1.00 | TLR7 (0.65) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4669726 | 0.92 | TLR7 (0.55) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4461897 | 0.90 | TLR7 (0.53) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL2060179 | 0.90 | TLR7 (0.52) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4459439 | 0.88 | TLR7 (0.67) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4465076 | 0.88 | TLR7 (0.55) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL15726062 | 0.87 | TLR7 (0.53) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4460913 | 0.87 | TLR7 (0.55) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4474934 | 0.85 | TLR7 (0.62) | TLR7TMIGD3ADORA2AADORA2BADORA1 | |
| SCHEMBL4473247 | 0.84 | TLR7 (0.54) | TLR7TMIGD3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | claimed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | claimed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | claimed |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | NEKTAR THERAPEUTICS | 2021-05-06 | — | — | US | disclosed |
| EP-3668548-A2 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | Nektar Therapeutics (US) | 2020-06-24 | — | — | EP | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | CD274, TLR7, PDCD1LG2 | TLR7 2/4885TMIGD3 787/4885ADORA2A 172/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | TLR7 31/4885TMIGD3 3870/4885ADORA2A 11/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | TLR7 4/4885TMIGD3 3431/4885ADORA2A 61/4885 |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | CD274, TLR7, PDCD1LG2 | TLR7 2/4885TMIGD3 787/4885ADORA2A 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.